The volume of information attendees receive at the annual Transcatheter Cardiovascular Therapeutics (TCT) interventional cardiology conference can be overwhelming. So, to prepare for the meeting, here is a list of some key items that will be covered in sessions, live cases and late-breaking trial presentations. It includes videos, articles, news and U.S. Food and Drug Administration (FDA) clearances that will be among the hottest topics at this year’s TCT, in Washington, D.C., Oct. 30 - Nov. 2.
What You Need to Know to Prepare for TCT 2016
Videos, news and articles regarding the hottest topics and data presentations at the 2016 Transcatheter Cardiovascular Therapeutics annual meeting
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip was the subject of two studies, including use to aid heart transplant patients. Bottom right, the Boston Scientific Acurate neo TAVR valve performed below the Sapien 3 and CoreValve Evolut.
EchoPixel showed technology at TCT 2019 that creates live holograms in the cath lab from 3-D TEE imaging. It projects the holograms on a special display screen that does not require the user to wear 3-D glasses. The interventional cardiologist can use hand movements and a foot switch to move the image around without breaking the sterile field. It offers a new way to visualize catheters, device positioning and deployment in structural heart procedures. (Photos by Dave Fornell)